It's nice to see a detailed 4C. Despite the diminishing share price since mid-Feb there has been some great achievements in that period and the report details them well.
ALA is funded until preliminary data from Phase 1 trails and part of the focus this year is the further development of it's solid tumor products.
No red flags in this for mine.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.015(11.5%) |
Mkt cap ! $152.3M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.5¢ | 13.0¢ | $168.0K | 1.212M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 71428 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 5994 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| ALA (ASX) Chart |